UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
(Exact name of registrant as specified in its charter)
| (State
or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S.
Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including
area code: (
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 8.01 | Other Events. |
As previously disclosed, on October 1, 2021, Voyager Therapeutics, Inc. (the “Company”) entered into an option and license agreement (the “Agreement”) with Pfizer Inc. (“Pfizer”) pursuant to which the Company granted Pfizer options to receive an exclusive license (each a “License Option”) to novel capsids (“Capsids”) generated from the Company’s TRACER™ screening technology to develop and commercialize certain adeno-associated virus gene therapy candidates comprised of a Capsid and specified transgenes (the “Pfizer Transgenes”). Under the terms of the Agreement, Pfizer had the right, through September 30, 2022, to evaluate the potential use of the Capsids in combination with up to two Pfizer Transgenes to help treat central nervous system (“CNS”) and cardiovascular diseases.
On October 4, 2022, the Company announced that Pfizer has provided the Company notice of its decision to exercise its License Option with respect to a Capsid in connection with a gene therapy program for the potential treatment of an undisclosed rare neurologic, CNS disease (the “Option Exercise”). Under the terms of the Agreement, the Company is entitled to receive a fee of $10 million with respect to the Option Exercise and is eligible to receive potential future development, regulatory, commercialization and sales milestone payments and potential royalties with respect to a gene therapy product incorporating the licensed Capsid for the treatment of the rare neurologic, CNS disease. Pfizer did not exercise its option to license a Capsid for a specified cardiovascular disease target under the Agreement. As a result, all rights to Capsids for that cardiovascular disease target under the Agreement have expired and have reverted to Voyager.
The foregoing description of the Agreement is qualified in its entirety by the text of the Agreement, a copy of which was filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending September 30, 2021.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: October 4, 2022 | VOYAGER THERAPEUTICS, INC. | |
| By: | /s/ Alfred Sandrock, M.D., Ph.D. | |
| Alfred Sandrock, M.D., Ph.D. | ||
|
Chief Executive Officer, President, and Director (Principal Executive Officer) | ||